Shopping Cart
- Remove All
- Your shopping cart is currently empty
L-745870 is an orally active, selective, and efficient dopamine D4 receptor antagonist that crosses the blood-brain barrier. It also inhibits D2 receptors, 5-HT2 receptors, and α-adrenergic receptors, useful in neurological disease studies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $35 | In Stock | |
5 mg | $59 | In Stock | |
10 mg | $98 | In Stock | |
25 mg | $198 | In Stock | |
50 mg | $329 | In Stock | |
100 mg | $478 | In Stock | |
1 mL x 10 mM (in DMSO) | $63 | In Stock |
Description | L-745870 is an orally active, selective, and efficient dopamine D4 receptor antagonist that crosses the blood-brain barrier. It also inhibits D2 receptors, 5-HT2 receptors, and α-adrenergic receptors, useful in neurological disease studies. |
Targets&IC50 | D3 receptor (human):2300 nM (Ki), D4 receptor (human):0.43 nM (Ki), D2 receptor (human):960 nM (Ki) |
In vitro | L-745870 binds specifically to the human dopamine D4 receptor with a binding affinity (Ki) of 0.43 nM. L-745870 (0.1-1 μM) exhibits D4 receptor antagonist activity, reversing dopamine (1 μM) -mediated adenylate cyclase inhibition in hD4HEK and hD4CHO cells. [1] |
In vivo | L-745870 (0, 1, or 2 μg/5 μl,icv injection) acts on dopamine D4 receptors to reduce sucrose consumption in a dose-dependent manner in hedonic-fed rat models. [2] L-745870 (5 and 10 mg/kg, systemic injection) inhibited PFC slow rhythm (delta, 2-4 Hz) and enhanced HPCθ in rats. [3] |
Molecular Weight | 326.82 |
Formula | C18H19ClN4 |
Cas No. | 158985-00-3 |
Smiles | ClC1=CC=C(C=C1)N2CCN(CC3=CNC=4N=CC=CC43)CC2 |
Relative Density. | 1.31 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 16 mg/mL (48.96 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.